A Phase 3 interventional study of Cetuximab and Cisplatin/Carboplatin in Carcinoma, Squamous Cell of Head and Neck, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-13.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck — 11 open to participants now, 19 under way, 7 of them phase 3. Cetuximab · Squamous Cell Carcinoma of Head and Neck.
Among the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck, this one is the 12th largest by enrollment of the 84 interventional ones that give a count, is one of 6 that started in 2015, is one of 16 in phase 3, and was the 58th registered.
2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →11 of the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck are open now, in 4 countries. Recruiting first, the newest first:
NRG Oncology · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello · Sites in Spain
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Sites in China
Ages 18+
By country, each count listing its studies:
Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 51 · Phase 3 18
First in 1999; this study’s year is marked. 6 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 243 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 46 across the 84 interventional studies. Of the 59 that completed or were terminated, 32 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 86 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
10 studies in Squamous Cell Carcinoma of Head and Neck by Merck KGaA, Darmstadt, Germany: 1 open now, 1 under way, none of them phase 3. Of 9 finished, 6 (67%) have results posted.
Among the 10 studies in Squamous Cell Carcinoma of Head and Neck by Merck KGaA, Darmstadt, Germany, this one is the only one that started in 2015, is one of 4 in phase 3, and was the 8th registered.
Merck KGaA, Darmstadt, Germany’s Squamous Cell Carcinoma of Head and Neck studies by the year they started, since 2009.
4 of the studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04375384Wake Forest University Health SciencesCetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer | 2026-12 |
| NCT06978829Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityCetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC | 2027-03-31 |
| NCT04722523Memorial Sloan Kettering Cancer CenterA Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer | 2027-06-20 |
| NCT06869473Gruppo Oncologico del Nord-OvestCetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19. | 2027-08-20 |
Add all 4 to your calendar (.ics) → With an account.
Among the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck, from their registry updates:
Among Merck KGaA, Darmstadt, Germany’s 10 in Squamous Cell Carcinoma of Head and Neck:
This tab as a report to print or save as PDF → With an account.
This trial aimed to assess efficacy and safety of cetuximab when given in combination with chemotherapy compared with chemotherapy alone in Chinese participants with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) as the first-line treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Cetuximab · Drug: Cisplatin/Carboplatin · Drug: 5-fluorouracil
Drug: Cisplatin/Carboplatin · Drug: 5-fluorouracil
Participants received Cetuximab as an intravenous infusion at an initial dose of 400 milligrams per square meter (mg/m\^2) on Day 1 and a subsequent dose of 250 mg/m\^2 on Day 8 and Day 15 of each 21-day treatment cycle.
Also known as: Erbitux
Drug pages: Cisplatin · Carboplatin
Cisplatin or Carboplatin (at an equivalent dose in case of intolerability of cisplatin) was administered at a dose of 75 mg/m\^2 as an intravenous infusion on Day 1 of each 21-day treatment cycle.
Participants received 5-fluorouracil (FU) at a dose of 750 mg/m\^2/day as a continuous intravenous infusion over 24 hours a day from Day 1 to Day 5 of each 21-day treatment cycle.
Also known as: 5-FU
Progression-free Survival (PFS) Time, as Assessed by an Independent Review Committee (IRC)
PFS time was defined as the time in months from the date of randomization until first observation of PD (based on imaging as assessed by IRC), or death due to any cause when death occurs within 60 days after the last tumor assessment or randomization (whichever is later). PD is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on trial; and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 millimeter. PFS was measured using Kaplan-Meier (KM) estimates.
Time frame: Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)
Progression-free Survival (PFS) Time, as Assessed by the Investigator
PFS time was defined as the time in months from the date of randomization until first observation of PD (radiologically confirmed by Investigator), or death due to any cause when death occurs within 60 days after the last tumor assessment or randomization (whichever is later). PD is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on trial; and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 millimeter. PFS was measured using Kaplan-Meier (KM) estimates.
Time frame: Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)
Overall Survival (OS) Time
The OS time was defined as the time from randomization to the date of death. If a participant was alive at the time of analysis, survival time was censored at the last date when the participant was known to be alive. If this date was after data cut-off, participants were censored at the date of data cut-off. OS was measured using Kaplan-Meier (KM) estimates.
Time frame: Time from date of randomization up to data cutoff (assessed up to 904 days)
Best Overall Response Rate (ORR)
The Best ORR was based on imaging and classified according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria. The BOR rate was defined as the number of participants whose BOR was either complete response (CR) or partial response (PR), relative to the number of participants belonging to the trial set of interest. CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)
Disease Control Rate (DCR)
The DCR was based on imaging and classified according to RECIST Version 1.1 criteria. The DCR was defined as the number of participants whose Best Overall Response is either CR, PR or stable disease (SD), divided by the number of participants belonging to the trial set of interest multiplied by 100. CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on trial.
Time frame: Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)
Duration of Response (DOR)
DOR was determined for participants whose BOR was either CR or PR. It was defined as the time from the first assessment of CR or PR until the event defining PFS time. PFS time was defined as the time in months from the date of randomization until first observation of PD (based on imaging as assessed by IRC), or death due to any cause when death occurs within 60 days after the last tumor assessment or randomization (whichever is later). CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs), Treatment Emergent Adverse Events Leading to Death and AEs Leading to Discontinuation
An Adverse event (AE) was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug that were absent before treatment or that worsened relative to pre-treatment state up to 30 days after last administration. TEAEs included both Serious TEAEs and non-serious TEAEs.
Time frame: Time from date of randomization up to data cutoff (assessed up to 904 days)
First participant signed informed consent: 31 Jul 2015, Clinical data cut-off: 19 Jan 2018.
| Milestone | Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | Cisplatin/Carboplatin + 5-Flurouracil |
|---|---|---|
| Started | 164 | 79 |
| Completed | 138 | 72 |
| Not completed | 26 | 7 |
| Withdrew: Ongoing at clinical cut-off date | 25 | 4 |
| Withdrew: Randomized, but not treated | 1 | 3 |
PFS time was defined as the time in months from the date of randomization until first observation of PD (based on imaging as assessed by IRC), or death due to any cause when death occurs within 60 days after the last tumor assessment or randomization (whichever is later). PD is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on trial; and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 millimeter. PFS was measured using Kaplan-Meier (KM) estimates.
| months | Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | Cisplatin/Carboplatin + 5-Flurouracil |
|---|---|---|
| Progression-free Survival (PFS) Time, as Assessed by an Independent Review Committee (IRC) | 5.5 (5.4 to 5.6) | 4.2 (3.0 to 5.3) |
PFS time was defined as the time in months from the date of randomization until first observation of PD (radiologically confirmed by Investigator), or death due to any cause when death occurs within 60 days after the last tumor assessment or randomization (whichever is later). PD is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on trial; and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 millimeter. PFS was measured using Kaplan-Meier (KM) estimates.
| months | Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | Cisplatin/Carboplatin + 5-Flurouracil |
|---|---|---|
| Progression-free Survival (PFS) Time, as Assessed by the Investigator | 5.5 (5.5 to 5.7) | 4.6 (2.9 to 5.5) |
The OS time was defined as the time from randomization to the date of death. If a participant was alive at the time of analysis, survival time was censored at the last date when the participant was known to be alive. If this date was after data cut-off, participants were censored at the date of data cut-off. OS was measured using Kaplan-Meier (KM) estimates.
| months | Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | Cisplatin/Carboplatin + 5-Flurouracil |
|---|---|---|
| Overall Survival (OS) Time | 10.2 (9.3 to 11.5) | 8.4 (6.5 to 9.9) |
The Best ORR was based on imaging and classified according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria. The BOR rate was defined as the number of participants whose BOR was either complete response (CR) or partial response (PR), relative to the number of participants belonging to the trial set of interest. CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | Cisplatin/Carboplatin + 5-Flurouracil |
|---|---|---|
| Best Overall Response Rate (ORR) | 50 (42.1 to 57.9) | 26.6 (17.3 to 37.7) |
The DCR was based on imaging and classified according to RECIST Version 1.1 criteria. The DCR was defined as the number of participants whose Best Overall Response is either CR, PR or stable disease (SD), divided by the number of participants belonging to the trial set of interest multiplied by 100. CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on trial.
| percentage of participants | Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | Cisplatin/Carboplatin + 5-Flurouracil |
|---|---|---|
| Disease Control Rate (DCR) | 75.6 (68.3 to 82.0) | 59.5 (47.9 to 70.4) |
DOR was determined for participants whose BOR was either CR or PR. It was defined as the time from the first assessment of CR or PR until the event defining PFS time. PFS time was defined as the time in months from the date of randomization until first observation of PD (based on imaging as assessed by IRC), or death due to any cause when death occurs within 60 days after the last tumor assessment or randomization (whichever is later). CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Weeks | Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | Cisplatin/Carboplatin + 5-Flurouracil |
|---|---|---|
| Duration of Response (DOR) | 18.1 (13.1 to 20.3) | 13.9 (8.7 to 18.1) |
An Adverse event (AE) was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug that were absent before treatment or that worsened relative to pre-treatment state up to 30 days after last administration. TEAEs included both Serious TEAEs and non-serious TEAEs.
| Participants | Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | Cisplatin/Carboplatin + 5-Flurouracil |
|---|---|---|
| TEAEs | 163 | 75 |
| TESAEs | 46 | 21 |
| TEAEs Leading to Death | 11 | 8 |
| AEs Leading to Discontinuation | 27 | 8 |
Collected over Time from date of randomization up to data cutoff (assessed up to 904 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | 105/163 (64.4%) | 46/163 (28.2%) | 163/163 (100%) |
| Cisplatin/Carboplatin + 5-Flurouracil | 54/76 (71.1%) | 21/76 (27.6%) | 73/76 (96.1%) |
| Event | Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | Cisplatin/Carboplatin + 5-Flurouracil |
|---|---|---|
| Lung infectionInfections and infestations | 6/163 | 4/76 |
| Tumor haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/163 | 3/76 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/163 | 0/76 |
| AnaemiaBlood and lymphatic system disorders | 1/163 | 2/76 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/163 | 2/76 |
| Upper respiratory tract infectionInfections and infestations | 0/163 | 2/76 |
| White blood cell count decreasedInvestigations | 0/163 | 2/76 |
| Obstructive airways disorderRespiratory, thoracic and mediastinal disorders | 0/163 | 2/76 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/163 | 1/76 |
| Atrial fibrillationCardiac disorders | 0/163 | 1/76 |
| Event | Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | Cisplatin/Carboplatin + 5-Flurouracil |
|---|---|---|
| NauseaGastrointestinal disorders | 93/163 | 51/76 |
| Weight decreasedInvestigations | 103/163 | 31/76 |
| VomitingGastrointestinal disorders | 60/163 | 37/76 |
| AnaemiaBlood and lymphatic system disorders | 73/163 | 36/76 |
| RashSkin and subcutaneous tissue disorders | 77/163 | 1/76 |
| ConstipationGastrointestinal disorders | 73/163 | 31/76 |
| Decreased appetiteMetabolism and nutrition disorders | 67/163 | 34/76 |
| White blood cell count decreasedInvestigations | 62/163 | 25/76 |
| NeutropeniaBlood and lymphatic system disorders | 58/163 | 22/76 |
| HypokalaemiaMetabolism and nutrition disorders | 56/163 | 18/76 |
Intention-to-treat (ITT) analysis set included all participants who were randomized to study treatment.
| Age, Continuous(years) | Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | Cisplatin/Carboplatin + 5-Flurouracil | Total |
|---|---|---|---|
| Mean | 57.1 ± 9.52 | 57.0 ± 8.99 | 57.1 ± 9.34 |
| Sex: Female, Male(Participants) | Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | Cisplatin/Carboplatin + 5-Flurouracil | Total |
|---|---|---|---|
| Female | 18 | 12 | 30 |
| Male | 146 | 67 | 213 |
| Ethnicity (NIH/OMB)(Participants) | Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | Cisplatin/Carboplatin + 5-Flurouracil | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 0 | 0 | 0 |
| Unknown or Not Reported | 164 | 79 | 243 |
| Race (NIH/OMB)(Participants) | Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | Cisplatin/Carboplatin + 5-Flurouracil | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 164 | 79 | 243 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2015 to primary completion in Jan 2018, 29 months.
Results were first posted in Apr 2019, 1 year 2 months after primary completion.
Of 78 phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 117. This study's 29 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cetuximab
Squamous Cell Carcinoma of Head and Neck →
Merck KGaA, Darmstadt, Germany →